CRH


9m 22: Resilient performance overall despite FX headwinds

22/11/22 -"CRH’s 9-month results were in line with our expectations. Sales were up by 13% to $24.4bn and EBITDA up by 14% to $4.2bn despite FX headwinds. The EBITDA margin was up by 10bps. This ..."

Pages
62
Language
English
Published on
22/11/22
You may also be interested by these reports :
28/11/22
The good, the bad and the ugly

23/11/22
Destocking in November is far more brutal than expected by EU chemical companies in its 3Q22 conference calls and might trigger inventory ...

22/11/22
CRH’s 9-month results were in line with our expectations. Sales were up by 13% to $24.4bn and EBITDA up by 14% to $4.2bn despite FX headwinds. The ...

22/11/22
Building Materials are too expensive when it comes to the price of a bag of cement or some shiny bathroom ceramics. Corporates have pleased ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO